Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of Akatinol Memantine in Moderate Cognitive Impairments

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

A six-month open clinical trial of the efficacy of Akatinol was conducted in 40 patients with moderate cognitive impairments (MCI) using piracetam (20 patients) as reference agent; mean age was 67.7 ± 7.2 years. Patient status was evaluated using a number of scales, questionnaires, and neuropsychological tests prior to treatment and at three and six months of treatment. Akatinol was given at a dose of 10 mg/day, and 20 patients received piracetam at a dose of 1200 mg/day. Studies were completed by 38 patients (95%) in the Akatinol arm and 18 (90%) in the piracetam arm. In the group treated with Akatinol, 5% reported deterioration, 20% no change, 35% moderate improvement, 25% marked improvement, and 15% great improvement. In the Akatinol arm, the proportion of patients without effects was significantly lower, while the proportions of patients with marked and great improvements were significantly higher than in the piracetam arm. Overall evaluation of cognitive functions on the MMSE scale showed significant increases in both groups by the end of the third month, though only patients receiving Akatinol maintained the improvements to the end of the sixth month. Akatinol treatment also produced positive changes in the symptoms of depression, subjective symptoms, and quality of life. More marked positive changes were seen in the dysregulatory type of MCI than in the amnestic type of MCI. The concept of MCI with a high risk of transformation to dementia is introduced; in this situation, treatment with Akatinol may be particularly relevant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zh. M. Glozman, Quantitative Evaluation of Neuropsychological Study Data [in Russian], Moscow (1999).

  2. I. V. Damulin, “Mild cognitive impairments,” Consilium Medicum, No. 2, 138–141 (2004).

  3. V. V. Zakharov and N. N. Yakhno, “Moderate cognitive impairments syndrome in the elderly: diagnosis and treatment,” Rus. Med. Zh., No. 10, 573–576 (2004).

    Google Scholar 

  4. O. S. Levin, “Diagnosis and treatment of moderate cognitive impairments in the elderly,” Zh. Nevrol. Psikhiat., No. 8, 42–49 (2006).

    Google Scholar 

  5. O. S. Levin and L. V. Golubeva, “Heterogeneity of moderate cognitive impairment: diagnostic and therapeutic aspects,” Consilium, No. 12, 106–110 (2006).

  6. O. S. Levin, M. M. Sagova, and L. V. Golubeva, “Factors influencing quality of life in patients with cerebral ischemia with moderate cognitive impairment,” Rus. Med. Zh., No. 3, 25–29 (2006).

    Google Scholar 

  7. A. R. Luriya, Cortical Functions in Humans and Their Impairment in Local Brain Lesions [in Russian], Moscow State University, Moscow (1969).

    Google Scholar 

  8. A. Yu. Panasyuk, An Adapted Version of the Wechsler Scale [in Russian], Science Research Institute Psychiatry, Ministry of Health of the Russian Federation, Moscow (1983).

    Google Scholar 

  9. N. N. Yakhno and V. V. Zakharov, “Cognitive and emotional-affective impairments in cerebral ischemia,” Rus. Med. Zh., No. 10, 539–542 (2002).

  10. P. Ahmed, J. Mitchell, and R. Arnold, “Rapid clinical progression in amnestic mild cognitive impairment,” Dement. Geriat. Cogn. Disord., 25, 170–177 (2008).

    Article  Google Scholar 

  11. L. G. Apostolova and J. L. Cummings, “Neuropsychiatric manifestations in mild cognitive impairment,” Dement. Geriat. Cogn. Disord., 25, 115–126 (2008).

    Article  Google Scholar 

  12. A. T. Beck, C. H. Ward, M. Mendelson, et al., “An inventory for measuring depression,” Arch. Gen. Psychiat., 4, 561–571 (1961).

    CAS  PubMed  Google Scholar 

  13. R. Brooks, R. Rabin, and F. de Charro, The Measurement and Valuation of Health Status Using EQ-5D, Kluwer Academic Publishers, Dordrecht (2003).

    Google Scholar 

  14. S. DeKosky, J. Williamson, A. L. Fitzpatrick, et al., “Ginkgo biloba for prevention of dementia,” J. Amer. Med. Assoc., 300, 2253–2262 (2008).

    Article  CAS  Google Scholar 

  15. B. Dubois, H. Feldman, C. Jacova, et al., “Research criteria for the diagnosis of Alzheimer’s disease revising NINCDS-ADRDA criteria,” Lancet Neurology, 6, 734–746 (2007).

    Article  PubMed  Google Scholar 

  16. K. Fassbender, M. Simons, C. Bergmann, et al., “Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo,” Proc. Natl. Acad. Sci. USA, 98, 5856–5861 (2001).

    Article  CAS  PubMed  Google Scholar 

  17. H. H. Feldman, S. Ferris, B. Winblad, et al., “Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study,” Lancet Neurology, 6, 501–512 (2007).

    Article  CAS  PubMed  Google Scholar 

  18. M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-mental status,” J. Psychiat. Res., 12, 189–196 (1975).

    Article  CAS  PubMed  Google Scholar 

  19. F. Forette, M. Seux, J. Staessen, et al., “Prevention of dementia in Syst-Eur trail,” Lancet, 352, 1347–1351 (1998).

    Article  CAS  PubMed  Google Scholar 

  20. P. T. Francis, “Behavioral effects of memantine: understanding the pharmacological rationale,” Eur. J. Neurosci., 14, Suppl. 1, 14 (1998).

    Google Scholar 

  21. S. Gauthier and J. Touchon, “Subclassification of mild cognitive impairment in research and in clinical practice,” Alzheimer’s Disease and Related Disorders Annual, 61–70 (2004).

  22. S. Gauthier, Y. Wirth, and H. J. Mobius, “Effects of memantine on behavioral symptoms in Alzheimer disease patients,” Int. J. Geriat. Psychiat., 20, 459–464 (2005).

    Article  CAS  Google Scholar 

  23. R. K. Heaton, Wisconsin Card Sorting Test Manual, Psychological Assessment Resources, Odessa, FL (1981).

    Google Scholar 

  24. V. Jelic, M. Kivipelto, and B. Winblad, “Clinical trials in mild cognitive impairment: lessons for the future,” J. Neurol. Neurosurg. Psychiat., 77, 429–438 (2006).

    Article  CAS  PubMed  Google Scholar 

  25. M. Kivipelto, E. L. Helkala, T. Hanninen, et al., “Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study,” Neurology, 56, 1683–1689 (2001).

    CAS  PubMed  Google Scholar 

  26. S. Larrieu, L. Letenneur, J. M. Orgogozo, et al., “Incidence and outcome of mild cognitive impairment in a population-based prospective cohort,” Neurology, 59, 1594–1599 (2002).

    CAS  PubMed  Google Scholar 

  27. H. Lehfield and H. Erzigkeit, “The SKT-A Short Cognitive Performance Test for Assessing Deficits of Memory and Attention,” Int. Psychogeriatrics, 9, 115–121 (1997).

    Article  Google Scholar 

  28. L. Li, A. Sengupta, N. Haque, et al., “Memantine inhibits and reverses the Alzheimer’s type abnormal hyperphosphorylation of tau and associated neurodegeneration,” FEBS Lett., 566, 261–269 (2004).

    Article  CAS  PubMed  Google Scholar 

  29. P. J. Manos and R. Wu, “The ten point clock test,” Int. J. Psychiat. Med., 24, 229–244 (1994).

    Article  CAS  Google Scholar 

  30. B. McGuiness, S. Todd, A. P. Passmore, et al., “Systematic review: blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia,” J. Neurol. Neurosurg. Psychiat., 79, 4–5 (2008).

    Article  Google Scholar 

  31. M. A. Mintun, G. N. Larossa,Y. I. Sheine, et al., “[11C]PIB in a non-demented population: potential antecedent marker of Alzheimer disease,” Neurology, 67, 446–452 (2006).

    Article  CAS  PubMed  Google Scholar 

  32. A. J. Mitchell and M. Shiri-Feshki, “Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis,” J. Neurol. Neurosurg. Psychiat., 79, 1386–1391 (2008).

    Article  CAS  PubMed  Google Scholar 

  33. A. J. Mitchell and M. Shiri-Feshki, “Rate of progression of mild cognitive impairment to dementia,” Acta Psychiat. Scand., DOI:10.1111/j.1600-0447.2008.01326.x (2009).

  34. P. J. Mondrego and J. Fernandez, “Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study,” Arch. Neurol., 61, 1290–1293 (2004).

    Article  Google Scholar 

  35. J. C. Morris and J. Cummings, “Mild cognitive impairment (MCI) represents early-stage Alzheimer’s disease,” J. Alzheimer’s Dis., 7, 235–239 (2005).

    Google Scholar 

  36. J. M. Orgogozo, A. S. Rigaud, A. Stöffer, et al., “Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300),” Stroke, 33, 1834–1839 (2002).

    Article  CAS  PubMed  Google Scholar 

  37. K. Palmer, A. K. Berger, R. Monastero, et al., “Predictors of progression from mild cognitive impairment to Alzheimer disease,” Neurology, 68, 1596–1602 (2007).

    Article  CAS  PubMed  Google Scholar 

  38. E. R. Peskind, S. G. Potkin, N. Pomara et al., “Memantine treatment in mild to moderate Alzheimer’s disease,” Am. J. Geriat. Psychiat., 14, 704–715 (2006).

    Article  Google Scholar 

  39. R. C. Peterson, G. E. Smith, S. C. Waring, et al., “Mild cognitive impairment: clinical characterization and outcome,” Arch. Neurol., 56, 303–308 (1999).

    Article  Google Scholar 

  40. R. C. Petersen, R. Doody, A. Kurz, et al., “Current concepts in mild cognitive impairment,” Arch. Neurol., 58, 1985–1992 (2001).

    Article  CAS  PubMed  Google Scholar 

  41. R. C. Petersen, J. C. Stevens, M. Ganguli, et al., “Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology,” Neurology, 56, 1133–1142 (2001).

    CAS  PubMed  Google Scholar 

  42. R. C. Petersen, R. G. Thomas, M. Grundman, et al., “Vitamin E and donepezil for the treatment of mild cognitive impairment,” N. Eng. J. Med., 352, 2379–2388 (2005).

    Article  CAS  Google Scholar 

  43. F. Portet, P. J. Ousset, P. J. Visser, et al., “Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer’s Disease,” J. Neurol. Neurosurg. Psychiat., 77, 714–718 (2006).

    Article  CAS  PubMed  Google Scholar 

  44. B. Reisberg, R. Doody, A. Stoffler, et al., “Memantine in moderate-tosevere Alzheimer’s disease,” N. Eng. J. Med., 348, 1333–1341 (2003).

    Article  CAS  Google Scholar 

  45. D. R. Royall, “Executive cognitive impairment: a novel perspective on dementia,” Neuroepidemiology, 19, 293–299 (2000).

    Article  CAS  PubMed  Google Scholar 

  46. S. Salloway, S. Ferris, A. Kluger, et al., “Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial,” Neurology, 63, 651–657 (2004).

    CAS  PubMed  Google Scholar 

  47. M. Sarazin, C. Berr, and J. de Rotrou, “Amnestic syndrome of the medial temporal type identifies prodromal AD,” Neurology, 69, 1859–1867 (2007).

    Article  CAS  PubMed  Google Scholar 

  48. P. Seeman, C. Caruso, and M. Lasaga, “Memantine agonist action at dopamine d2high receptors,” Synapse, 62, 149–153 (2008).

    Article  CAS  PubMed  Google Scholar 

  49. R. Spanagel, B. Eilbacher, and R. Wilke, “Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat – a pharmacokinetic microdialysis study,” Eur. J. Pharmacol., 262, 21–26 (1994).

    Article  CAS  PubMed  Google Scholar 

  50. S. E. Starkstein, H. S. Mayberg, T. J. Preziosi, et al., “Reliability, validity, and clinical correlates of apathy in Parkinson’s disease,” J. Neuropsychiat. Clin. Neurosci., 4, 134–139 (1992).

    CAS  Google Scholar 

  51. P. T. Tariot, M. R. Farlow, G. R. Grossberg, et al., “Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial,” J. Am. Med. Assoc., 291, 317–324 (2004).

    Article  CAS  Google Scholar 

  52. B. Winblad, R. Jones, Y. Wirth, et al., “Memantine in moderate to severe Alzheimer’s disease: meta-analysis of randomized clinical trials,” Dement. Geriat. Cogn. Disord., 24, 20–27 (2007).

    Article  CAS  Google Scholar 

  53. B. Winblad, S. Gauther, L. Scinto, et al., “Safety and efficacy of galantamine in subjects with mild cognitive impairment,” Neurology, 70, 2024–2035 (2008).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Russian Postgraduate Medical Academy, Moscow, Russia

    O. S. Levin, N. A. Yunishchenko & M. A. Dudarova

Authors
  1. O. S. Levin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. A. Yunishchenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. A. Dudarova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. S. Levin.

Additional information

Translated from Zhurnal Nevrologii i Psikhatrii imeni S. S. Korsakova, Vol. 109, No. 7, pp. 36–42, July, 2009.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levin, O.S., Yunishchenko, N.A. & Dudarova, M.A. Efficacy of Akatinol Memantine in Moderate Cognitive Impairments. Neurosci Behav Physi 40, 926–933 (2010). https://doi.org/10.1007/s11055-010-9347-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-010-9347-8

Key words

Search

Navigation